

2 (Amended) The polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of a naturally-occurring allelic variant of an amino acid sequence of SEQ ID NO:4.

B1
3. (Amended) The polypeptide of claim 2, wherein said allelic variant comprises an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a nucleic acid sequence of SEQ ID NO:3.

4. The polypeptide of claim 1, wherein the amino acid sequence of said variant comprises a conservative amino acid substitution.

36. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically-acceptable carrier.

39. A kit comprising in one or more containers, the pharmaceutical composition of claim 36.

51. (New) A method of producing the polypeptide of claim 1, the method comprising culturing a cell under conditions that lead to expression of the polypeptide, wherein said cell comprises a vector comprising an isolated nucleic acid molecule of SEQ ID NO: 3.

B2
52. (New) The method of claim 51 wherein the cell is a bacterial cell.

53. (New) The method of claim 51 wherein the cell is an insect cell.

54. (New) The method of claim 51 wherein the cell is a yeast cell.

55. (New) The method of claim 51 wherein the cell is a mammalian cell.